Quantum A Matter of Life L3-5, 3rd Floor Wisma Kemajuan, No.2, Jalan 19/1B, 46300 Petaling Jaya, Selangor. T. 1300-13-3522 (Co no. 941541-V) Quantum Diagnostics Sdn Bhd QUANTUM MEDICAL UPDATE www.quantumdxs.com Bringing Science to LIFE Issue 3 MS ISO 15189 The key points from the study are as follows: 1. iM2PK is significantly more sensive in the detecon of CRC than FOBT. iM2PK had a test sensivity of 97.5% vs FOBT with a test sensivity of 47.5%. Test specificity from both tests was equal at 100.0%. This means that as a screening tool for CRC, iM2PK is twice as sensive as FOBT at detecng CRC with an equally low false posive rate. 2. iM2PK is significantly more sensive in the detecon of adenoma than FOBT. iM2PK had a test sensivity of 69.2% vs FOBT with a test sensivity of 19.2%. Test specificity from both tests was equal at 100.0%. Adenomas (adenomatous polyps) >5mm in size have potenal of developing into CRC, with the risk of carcinogenesis increasing with size (Adenomas >20mm have a 50% chance of becoming malignant). 3. iM2PK has a significantly higher negave predicve value (NPV) in CRC detecon than FOBT. iM2PK has a NPV of 83.3% vs FOBT with a NPV of 40.7%. The NPV of iM2PK is double that of FOBT which means that clinicians can inform paents of their results with greater confidence (lower false negaves). Please find overleaf a how to guide on performing the M2PK Quick test. References: 1. Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: a meta-analysis. Tonus et al. World J Gastroenterol. 2012 Aug 14;18(30):4004-11. 2. The Usefulness of a Novel Screening Kit for Colorectal Cancer Using theImmunochromatographic Fecal Tumor M2 Pyruvate Kinase Test. Kim et al. Gut Liver. 2014 Dec 5. doi: 10.5009/gnl13457. [Epub ahead of print] Dear Colleague, Colorectal cancer (CRC) is the second most common cancer in Malaysian men and women – accounng for up to 12.3% of all reported cancers (Naonal Cancer Registry Report 2007). Unfortunately, 91% of Malaysian CRC cases diagnosed are Dukes B, C and D (Stage II, III, IV) which means lower cure rates, higher paent mortality and poorer overall outcomes. The reason for this is not just poor paent awareness about CRC and its presentaon, but also the lack of a sensive and convenient screening test. The M2PK Quick test is a novel non-invasive screening test for colorectal cancer (CRC) and colorectal polyps. Pyruvate kinase isoenzyme type M2 (M2PK) is an enzyme expressed by polyps and CRC cells which can be detected in stool. The M2PK test comes in a self collecon kit which allows immediate and convenient tesng by the paent or doctor. Alternavely, we may perform the test on your behalf at any of our collecon centres. We want to ensure that doctors are kept updated on the latest available data for our tests. This is important as new data/publicaons may highlight new issues with screening tests or broaden the uses of these tests in a clinical seng. A meta-analysis by Tonus et al published in the World Journal of Gastroenterology has already advocated the use of faecal M2PK as a roune test for CRC screening. The mean sensivity of faecal M2PK in CRC detecon was 81.1%, double that of FOBT at 36.9%. The test specificity of 95.2% also means a significantly lower rate of false posives. In this issue, we will update you on the results of the most recent M2PK study published by The Catholic University of Korea College of Medicine, South Korea. This is an important trial because the vast majority of previous studies and trials were carried out on European populaons. Given the differences in CRC prevalence, paent ethnicity and composion, lifestyles and diet, the results of the South Korean study are more applicable to our local populaon. Going forward, we will see increasingly more local data on M2PK as trials are currently being carried out in hospitals in Malaysia and Singapore. The South Korea study compared immunochromatographic M2PK (M2PK Quick test) against M2PK ELISA tesng and convenonal Faecal Occult Blood Test (FOBT) in the detecon of CRC and adenoma. All paents involved in the study underwent colonoscopy to confirm/exclude the diagnosis.